Print this page
immunotherapy
-
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors.
Protocol: 052008Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Any Site -
A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications.
Protocol: 052302Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors.
Protocol: 052402Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination with a MEK inhibitor PD-0325901 in Patients with Advanced or Refractory Solid Tumors.
Protocol: 052403Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Liver -
Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations.
Protocol: 072107Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Pancreas -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Colon -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Protocol: 072213Principal Investigator:
-
Sharon Li
Applicable Disease Sites: Liver -
A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2
Expression
Protocol: 072305Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Pancreas -
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy.
Protocol: 081602Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
Cyto-KIK TRIAL: (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).
Protocol: 082002Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Kidney -
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
Protocol: 082304Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Prostate -
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
-
Lara Hathout
Applicable Disease Sites: Kidney -
NCI 10204 - A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Protocol: 092305Principal Investigator:
-
Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
Protocol: 102302Principal Investigator:
-
Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers.
Protocol: 102402Principal Investigator:
-
Aliza Leiser
Applicable Disease Sites: Ovary